Reference entry · Dual-modified tuftsin analog
N-Acetyl Selank Amidate
Also known as: Ac-Selank-NH2 · Modified Selank with acetylation and amidation
- Class
- Dual-modified tuftsin analog
- Size
- 7 amino acids (N-acetyl, C-terminal amide)
- Primary targets (literature)
- Selank-related GABAergic and immunomodulatory literature
- Regulatory context
- Not FDA-approved. Must not be assumed equivalent to Selank without batch-specific identity data.
Overview
N-acetyl Selank amidate applies N-terminal acetylation and C-terminal amidation to the Selank heptapeptide sequence. Catalog listings treat it as a stabilized Selank derivative, but peer-reviewed literature on this exact modified sequence is thinner than for parent Selank.
Mechanism in research literature
Research framing references parent Selank anxiolytic and immunomodulatory models, with terminal modifications studied primarily for stability and permeability rather than independently validated new receptor targets.
Common research focus areas
- Dual terminal modification vs. parent Selank
- Sequence confirmation distinct from Semax analogs
- Stability research for modified neuropeptides
- Independent COA requirements for acetylated/amidated forms
Full literature roundup
Read the cited research summary
A dual-modified Selank derivative with acetylation and C-terminal amidation. Tuftsin analog context, stability chemistry, and batch identity standards.
N-Acetyl Selank Amidate research roundup · 6 minEvaluate catalog material
- COA literacy — read batch documentation before comparing vendors.
- Peptide identity testing — why sequence confirmation matters beyond purity %.
- How we vet sources — our score methodology for recommended vendors.